Vital Signs - Expanding Personalized Medicine Outside of Oncologic PET

 


This issue of Vital Signs, released on September 8, 2008, provides an strategic overview of the expansion of personalized medicine outside of oncologic PET. Additionally, a company spotlight is provided for Cell>Point, a company focused on the development of novel radiopharmaceutical agents for diagnostic and therapeutic applications in neurology, cardiology and oncology. Reimbursement and regulatory news from the FDA is also provided for the week of August 26, 2008.

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

Table of Contents

Vital Signs - Expanding Personalized Medicine Outside of Oncologic PETVital Signs: 8 September 2008This week's issue:




Related Research

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 24-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.